Close Menu

NEW YORK (GenomeWeb) – As soon as next year, individuals who have had exome sequencing from a company called Helix but deemed at low risk for cardiovascular disease or cancer will be able to use an app to get information about their genetic risks for these diseases from molecular testing firm Invitae.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.

CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.

A study of Great Danes homes in on a genomic region linked to fearfulness.

In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.